Anti-Cancer

Regorafenib (NUBLEXA) 40MG Tablet

$3,697.00

Regorafenib NUBLEXA 40 MG Tablet is a groundbreaking medication used in the treatment of advanced gastrointestinal stromal tumors (GIST), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC). It contains regorafenib as its active ingredient, a multi-targeted kinase inhibitor that inhibits several protein kinases involved in tumor angiogenesis, oncogenesis,

Quantity

Regorafenib (NUBLEXA) 40MG Tablet quantity

Add to cart

Tag:

Regorafenib NUBLEXA

Description

Regorafenib NUBLEXA 40 MG Tablet is a groundbreaking medication used in the treatment of advanced gastrointestinal stromal tumors (GIST), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC). It contains regorafenib as its active ingredient, a multi-targeted kinase inhibitor that inhibits several protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment.

Key Features:

• Multi-Targeted Kinase Inhibitor: Regorafenib exerts its therapeutic effects by inhibiting multiple protein kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptors (FGFRs), and oncogenic kinases such as RAF, RET, and KIT. This broad spectrum of activity inhibits tumor angiogenesis and growth, thereby slowing tumor progression.
• Treatment of Advanced Cancers: Regorafenib NUBLEXA 40 MG Tablet is indicated for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) who have progressed on prior treatment with imatinib and sunitinib, metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, and hepatocellular carcinoma (HCC) who have previously been treated with sorafenib.
• Oral Administration: Regorafenib NUBLEXA 40 MG Tablet is administered orally, typically once daily for 21 days followed by a 7-day rest period, constituting a 28-day treatment cycle. It can be taken with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical trials have demonstrated the efficacy of regorafenib in prolonging progression-free survival and overall survival in patients with advanced GIST, mCRC, and HCC. It has shown superiority over placebo and standard treatments, offering a valuable treatment option for patients with these challenging

Additional information